• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Schizopc Treatment

Schizopc Treatment






Total Views
Views on SlideShare
Embed Views



1 Embed 1

http://www.slideshare.net 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Schizopc Treatment Schizopc Treatment Presentation Transcript

    • Schizophrenia and Antipsychotic Treatment Stacy Weinberg 3 April 2007
    • What is it? •It is a severe, chronic, disabling brain disease •Considered to have biological origins but exact unknown •1% of population affected •“Schizophrenia” – split mind ● Multiple personality disorder is not schizophrenia •Psychosis is more accurate ● Severe mental illness where patient loses contact with reality ● People have problems thinking and feeling but are aware of their surroundings
    • Types 1. Catatonic Type • Either in position or speech (imitating others) • Very rare 2. Disorganized Type • Disturbance in behavior, speech, and thought • Flat affect, eccentric 3. Paranoid Type • Delusions and auditory hallucinations • Cognitive functioning remains intact 4. Residual Type • Have been previously diagnosed but no longer show prominent symptoms; still have other symptoms 5. Undifferentiated Type
    • Positive Symptoms • Disturbances of thought processes • Delusions • Hallucinations • Erratic/extreme emotions • Very slow or fast movement, catatonia • Behavioral changes
    • Negative Symptoms • Lack of interest/enjoyment in activities • Low energy/motivation • Blank facial expression, less facial variability • Inability to make or keep friends • Difficulty initiating activities • Social isolation
    • Causes - Dopamine Hypothesis • Genetic aspect • Most think it involves dopamine: – Elevation of D2 monomers, decrease of dimers – Increased release of dopamine • 2x higher • When given amphetamine, 2x more dopamine is released than control
    • Other Hypotheses • Dopamine hypothesis not agreed on by everyone • Some think excitatory amino acids like glutamate could play a role – One type of glutamate receptor, NMDA: NMDA antagonists (ex ketamine) can induce psychotic symptoms in non-schizophrenic patients – Found increase of NMDA receptors in postmortem studies of schizophrenic brains
    • Types of Drug Treatment 1. Typical Antipsychotics • Dopamine antagonists 2. Atypical Antipsychotics • 5-hydroxytryptamine effect, also effect dopamine 3. Combination Drugs
    • Typical • Tend to produce Extrapyramidal side effects: – Parkinsonism – tremors, rigidity, slowness of movement, temporary paralysis – Dystonia – involuntary muscle contractions – Akathisia – inability to resist urge to move – Tardive dyskinesia – involuntary movements of the mouth, lips, and tongue • Chewing, puckering, grimacing, etc.
    • Typical - Phenothiazines • Dopamine D2 receptor antagonists • Chlorpromazine first developed from promethazine, first tricyclic antihistamine Promethazine Chlorpromazine Trifluoperazine
    • Haloperidol • Butyrophenone • Used in 1970s almost exclusively • No anticholinergic effects – therefore used in patients with delirium
    • Atypicals • Atypicals do not induce EPSE • Block D2 receptors and 5-HT seratonin receptors (decreases EPSE) • As opposed to typicals, these are more loosely bound to D2 receptors – Easier dissociation – Shown that higher occupation of D2 receptors by drug, higher incidence of EPSE
    • 5-HT seratonin receptors • Blocking 5-HT seratonin receptors decreases negative symptoms and EPSE – Mechanism is unknown – Seratonin inhibits dopamine release – Positive symptoms associated with hyperdopaminergic condition in limbic lobe – more D2 receptors here, so D2 blocking prevails – Negative symptoms associated with hypodopaminergic condition in frontal lobe – more 5- HT receptors here, so seratonin inhibits dopamine release – stabilizes dopamine level
    • Clozapine • First atypical (1990) • Most dangerous atypical: risk of agranulocytosis (severe decrease in WBC count) • Most effective in reducing EPSE, also in reducing negative symptoms – Increases Fos-positive neurons in the prefrontal cortex (shown to affect negative symptoms)
    • Risperidone • Low doses needed • Predominantly blocks D2, then 5-HT – Does not exhibit multireceptor action • Lacks anticholinergic activity – makes it better for youth, elderly • Problem – increases prolactin levels (shouldn’t give to people with breast cancer)
    • Olanzapine • Zyprexa is number one antipsychotic in sales (Eli Lilly) • Exhibits multireceptor action • Good for controlling mood symptoms • Available in a wafer • Problems: Sedation and weight gain
    • Combinations • Example is Symbyax – Combination of olanzapine and fluoxetine (Prozac) – Can also treat bipolar disorder • Combination of ziprasidone and clozapine – Can be used to combat treatment resistance • Combination of aripriprazole and clozapine